In a landmark decision for pediatric infectious disease medicine, the U.S. Food and Drug Administration (FDA) has officially granted approval to ViiV Healthcare for the use of Tivicay PD (dolutegravir) in the treatment of HIV-1 in pediatric patients weighing as little as 2 kg. This milestone marks the first time a second-generation integrase strand transfer inhibitor (INSTI) has been authorized for use in newborns from birth, effectively removing the previous age-based barriers to care and providing a critical lifeline for the most vulnerable infants.
The approval represents a significant shift in the landscape of perinatal HIV management. By lowering the weight threshold to 2 kg (approximately 4.4 pounds) and eliminating the minimum-age requirement entirely, the FDA is addressing a long-standing "treatment gap" that has historically left clinicians with limited, often outdated options for infants born with or exposed to the virus.
The Evolution of Tivicay PD: A Chronology of Progress
The journey toward this approval has been one of incremental, evidence-based expansion. The story of dolutegravir’s role in pediatric care is a testament to the rigorous clinical study required to translate adult therapeutic success into safe pediatric practice.
- August 2013: The FDA first granted approval for Tivicay (dolutegravir) for use in adults and adolescents aged 12 years or older who weighed at least 40 kg (88.2 lbs). This set the foundation for the drug’s role as a potent and well-tolerated component of antiretroviral therapy (ART).
- 2020: Recognizing the need for child-friendly formulations, the FDA approved the dispersible tablet formulation, Tivicay PD. At that time, the indication was restricted to patients at least four weeks old and weighing at least 3 kg (6.6 lbs).
- 2025–2026: The IMPAACT 2023 study, funded by the National Institutes of Health (NIH), provided the necessary pharmacokinetic and safety data to support further expansion.
- August 2026: The FDA officially authorized the use of Tivicay PD in neonates weighing 2 kg or more from birth, finalizing the path for the youngest possible intervention.
Supporting Data: The IMPAACT 2023 Study
The foundation for this expanded indication rests upon the IMPAACT 2023 trial, a multicenter, phase 1 study that addressed one of the most difficult challenges in drug development: safely dosing a newborn whose metabolic systems are still rapidly maturing.
Researchers enrolled 48 mother-infant pairs across clinical sites in the United States, Thailand, and South Africa. The trial design focused on establishing the safety, tolerability, and pharmacokinetics of dolutegravir during the critical first four to six weeks of life. The study participants—newborns exposed to HIV-1—received Tivicay PD in combination with standard-of-care antiretroviral medications starting from birth.
Data presented to the FDA indicated that drug exposure levels in these newborns were comparable to those observed in adults, levels which are known to be highly effective in viral suppression. Furthermore, the safety profile in the neonates was consistent with that seen in older pediatric and adult populations, providing physicians with the confidence to transition from experimental usage to standard clinical practice.
A sub-cohort of 15 infants, who began treatment within the first five days of life, provided particularly granular data. These infants, weighing between 2.3 and 3.6 kg, followed a regimen of 5-mg tablets administered every other day for the first two weeks, transitioning to daily dosing thereafter. This dosing schedule allowed for a controlled, cautious introduction of the medication, ensuring that the neonatal liver and kidneys could process the drug effectively.
Official Responses and Clinical Perspectives
The medical community has hailed the decision as a vital advancement. Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and the lead investigator of the IMPAACT 2023 study, emphasized the clinical necessity of the change.
"For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Clarke stated. Her sentiment reflects the broader consensus among pediatric infectious disease specialists: that delaying treatment in HIV-positive infants is associated with significantly poorer long-term health outcomes.
The FDA’s decision to grant the application Priority Review status underscores the agency’s recognition of the urgent unmet medical need. By streamlining the review process, the FDA ensured that this therapeutic option reached the bedside of neonatal intensive care units (NICUs) as rapidly as possible, without compromising the rigor of the regulatory assessment.
Global Health Implications and Perinatal Transmission
While the number of perinatally acquired HIV infections in the United States has dropped to fewer than 50 cases annually since 2018—with a transmission rate of 1% or less—the global context remains dire. UNICEF reports that approximately 50% of children living with HIV will not survive past their second birthday if they do not receive timely antiretroviral therapy.
The approval of Tivicay PD for newborns is not merely a U.S.-centric regulatory victory; it serves as a global model for pediatric HIV care. By developing a dispersible, stable, and effective formulation, ViiV Healthcare has created a tool that can be exported to resource-limited settings where the burden of pediatric HIV remains highest. The ability to initiate treatment from birth, rather than waiting for the four-week mark, allows health systems to intervene before the virus can cause irreparable damage to the infant’s developing immune system.
Financial Context and the GSK/ViiV Portfolio
From a commercial perspective, the expansion of the Tivicay label serves as a strategic pillar for ViiV Healthcare, a majority-owned subsidiary of GSK. While the standalone Tivicay brand has seen a stabilization in its sales performance—reporting £1.323 billion in 2025, a slight decrease from the previous year—the broader HIV portfolio has continued to demonstrate robust growth.
In 2025, GSK’s total HIV portfolio revenue reached £7.687 billion, representing an 11% increase. This growth is primarily driven by the success of newer, long-acting, and combination products like Dovato, Cabenuva, and Apretude. However, the continued investment in the Tivicay line through pediatric indications highlights a commitment to a "full-lifecycle" approach to drug development. By ensuring that their core integrase inhibitors remain relevant across the entire human lifespan—from birth to old age—GSK/ViiV maintains a dominant position in the HIV therapeutic market.
Future Directions in Neonatal HIV Care
The approval of Tivicay PD for newborns is a significant milestone, but it also opens the door to further research. Future investigations will likely focus on:
- Optimization of Dosing Regimens: Refining the every-other-day dosing schedule to determine if simplified daily protocols can be safely implemented earlier in the neonatal period.
- Combination Therapies: Studying the interaction of dolutegravir with newer, long-acting injectable formulations, potentially reducing the pill burden for older pediatric patients.
- Long-term Neurodevelopmental Follow-up: Monitoring the infants treated in the IMPAACT 2023 study to ensure that early exposure to dolutegravir has no long-term impact on neurological development.
As it stands, the FDA’s decision is a triumph of pediatric clinical trial design. It moves the standard of care for HIV-positive newborns into the modern era of integrase inhibitors, providing parents and clinicians with a robust, well-studied tool to fight the virus at its earliest point of entry. In the ongoing battle to achieve an "AIDS-free generation," this approval is a definitive step forward, ensuring that even the smallest patients have the best possible chance at a healthy life.
About the Author
